Category: more about CM-24

Categories

• News and Events
  • Events
  • News
• Publications
  • CAPTN-3
  • CM-24
  • more about CM-24
  • more about NT-219
  • NT-219

Posts

• Purple Biotech to Present New Preclinical Data of IM1240 at the European Association for Cancer Research (EACR) 2026 Annual Congress which takes place June 8-11, 2026 in Budapest, Hungary.
• Toxicology study results in NHP validated improved PK and safety profile of CAPTN-3 masking design, revealing an extended therapeutic window
• Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress which takes place December 10-12, 2025 in London, UK.
• CAPTN-3 unique design demonstrated by 2 novel platform trispecific T Cell engagers
• Purple Biotech will participate in a fireside chat and 1×1 investor meeting at the H.C. Wainwright 27th Annual Global Investment Conference, being held September 8-10, 2025.
• CAPTN-3: A novel platform of conditionally activated T cell and NK cell engagers
• Final results of the randomized Phase 2 of CM24 in pancreatic cancer: Improved outcomes and significant efficacy in a serum biomarker-enriched subgroup
• APC-loss as a potential biomarker for NT219 treatment in colorectal cancer
• NT219 overcomes immune evasion mechanisms in head and neck squamous cell carcinoma (HNSCC)
• Purple Biotech to Participate in Panel Discussion at Canaccord Genuity Horizons in Oncology Virtual Conference on April 7, 2025